In an article, author is He, YanLing, once mentioned the application of 2516-96-3, Name is 2-Chloro-5-nitrobenzoic acid, molecular formula is C7H4ClNO4, molecular weight is 201.564, MDL number is MFCD00007294, category is chlorides-buliding-blocks. Now introduce a scientific discovery about this category, Recommanded Product: 2-Chloro-5-nitrobenzoic acid.
Glucosuric, renal and haemodynamic effects of licogliflozin, a dual inhibitor of sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2, in patients with chronic kidney disease: A randomized trial
Aim: To investigate the glucosuric, renal and haemodynamic effects of licogliflozin, a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 inhibitor, in patients with chronic kidney disease (CKD). Methods: This multiple-dose, parallel-group, phase II mechanistic study randomized 53 participants (aged 18-78 years, body mass index <= 50 kg/m(2)) with varying degrees of CKD or normal renal function to treatment with licogliflozin (50 mg once daily) or placebo for 7 days. The effects of licogliflozin on 24-h urinary glucose excretion (UGE(24)), renal function, haemodynamics, pharmacokinetics and safety were assessed. Results: Licogliflozin treatment for 7 days significantly (p < .01) increased UGE(24) from baseline in participants with normal renal function (adjusted mean change: 41.8 [33.6, 49.9] g) or with mild (32.6 [24.1, 41.0] g), moderate A (35.7 [28.6, 42.9] g) or moderate B (20.3 [13.1, 27.5] g) CKD, but not in severe (6.2 [-0.71, 13.18] g) CKD. Licogliflozin reduced urinary electrolytes (sodium, potassium and chloride), blood pressure and urinary volume to varying extents among different groups. Significant increases in renin (p < .05), angiotensin II (p < .05) and aldosterone (p < .01) levels were observed. Adverse events were generally mild, and most commonly included diarrhoea (94%), flatulence (68%) and abdominal pain (21%). Conclusion: Licogliflozin treatment results in significantly increased UGE and favourable changes in urinary electrolytes and haemodynamics in patients with varying degrees of CKD (estimated glomerular filtration rate >= 45 mL/min/1.73 m(2)).
Do you like my blog? If you like, you can also browse other articles about this kind. Thanks for taking the time to read the blog about 2516-96-3, Recommanded Product: 2-Chloro-5-nitrobenzoic acid.